英文名称 | CAS号 | 中文名 | 中文别名 | 分子式 | 分子量 | EINECS号 |
---|---|---|---|---|---|---|
TG-101348
|
936091-26-8 |
N-(1,1-二甲基乙基)-3-[[5-甲基-2-[[4-[2-(1-吡咯烷基)乙氧基]苯基]氨基]-4-嘧啶基]氨基]苯磺酰胺
|
CS-57;N-(1,1-二甲基乙基)-3-[[5-甲基-2-[[4-[2-(1-吡咯烷基)乙氧基]苯基]氨基]-4-嘧啶基]氨基]苯磺酰胺;FEDRATINIB (SAR302503,TG101348),≥98%;SAR-302503;N-(1,1-二甲基乙基)-3-[[5-甲基-2-[[4-[2-(1-吡咯烷基)乙氧基]苯基]氨基]-4-嘧啶基]氨基]苯磺酰胺(SAR302503,TG101348);FEDRATINIB (SAR302503,TG101348);TG101348;TG 101348;FEDRATINIB;SAR 302503;TG-101348;TG 101348;TG-101348;TG 101348;SAR-302503;SAR 302503;SAR302503
|
C27H36N6O3S |
524.68 | |
TG101209
|
936091-14-4 |
N-(1,1-二甲基乙基)-3-[[5-甲基-2-[[4-(4-甲基-1-哌嗪基)苯基]氨基]-4-嘧啶基]氨基]苯磺酰胺
|
N-(1,1-二甲基乙基)-3-[[5-甲基-2-[[4-(4-甲基-1-哌嗪基)苯基]氨基]-4-嘧啶基]氨基]苯磺酰胺;TG101209;TG 101209;TG-101209;CS-94
|
C26H35N7O2S |
509.67 | |
Tariquidar
|
206873-63-4 |
N-[2-[[4-[2-(6,7-二甲氧基-3,4-二氢-1H-异喹啉-2-基)乙基]苯基]氨基甲酰基]-4,5-二甲氧基苯基]喹啉-3-甲酰胺
|
N-[2-[[4-[2-(6,7-二甲氧基-3,4-二氢-1H-异喹啉-2-基)乙基]苯基]氨基甲酰基]-4,5-二甲氧基苯基]喹啉-3-甲酰胺3-喹啉甲酰胺,N-[2-[[[4-[2-(3,4-二氢-6,7-二甲氧基-2(1H)-异喹啉基)乙基]苯基]氨基]羰基]-4,5-二甲氧基苯基]-;他立喹达;CS-678;N-[2-[[4-[2-(6,5-二甲氧基苯基]喹啉-3-甲酰胺;3-喹啉甲酰胺,5-二甲氧基苯基]-;TARIQUIDAR P-糖蛋白抑制剂;XR 9576;XR-9576;D06009
|
C38H38N4O6 |
646.73 | |
TAK-901
|
934541-31-8 |
5-[3-(乙基磺酰基)苯基]-3,8-二甲基-N-(1-甲基-4-哌啶基)-9H-吡啶并[2,3-B]吲哚-7-甲酰胺
|
TAK-901;CS-7;5-[3-(乙硫酰基)苯基]-3,8-二甲基-N-(1-甲基-4-哌啶基)-9H-吡啶并[2,3-B]吲哚-7-甲酰胺;5-[3-(乙基磺酰基)苯基]-3,3-B]吲哚-7-羧酰胺;5-[3-(乙基磺酰基)苯基]-3,3-B]吲哚-7-甲酰胺
|
C28H32N4O3S |
505 | |
Tadalafil
|
171596-29-5 |
西力士
|
他打那非;他达那非(西力士)CIALIS;他达那非;他地那非;西力士;(6R-12aR)-6-(1,3-苯并二噁茂-5-基)-2-甲基-2,3,6,7,12,12a-六氢化吡嗪并[1',2'-1,6]-吡啶并[3,4-b]吲哚-1,4-二酮;他达那非(标准品);西力士(他达那非)2KG
|
C22H19N3O4 |
389.4 | |
Sorafenib
|
284461-73-0 |
索拉非尼
|
索拉非尼碱;索拉替尼;索拉菲尼碱;索拉非尼-D3;索拉非尼-D5;对甲苯磺酸索拉非尼;索拉菲尼
|
C21H16CLF3N4O3 |
464.83 | |
SNX-2112
|
908112-43-6 |
SNX-2112;4-(6,6-DIMETHYL-4-OXO-3-(TRIFLUOROMETHYL)-4,5,6,7-TETRAHYDRO-1H-INDAZOL-1-YL)-2-((1R,4R)-4-HYDROXYCYCLOHEXYLAMINO)BENZAMIDE
|
|
C23H27F3N4O3 |
464 | |
SNS-314
|
1146618-41-8 |
N-(3-氯苯基)-N'-[5-[2-(噻吩并3,2-D]嘧啶-4-基氨基)乙基]-2-噻唑基]脲甲磺酸盐 (1:1)
|
N-(3-Chlorophenyl)-N'-[5-[2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl]-2-thiazolyl]urea methanesulfonate (1:1);SNS-314 Mesylate;M1-(3-chlorophenyl)-3-(5-(2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl)thiazol-2-yl)urea Mesylate;N-(3-Chlorophenyl)-N'-[5-[2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl]-2-thiazolyl]urea methanesulfonate (1:1) SNS-314 Mesylate;SNS-314 mesylate, >=98%;1-(3-chlorophenyl)-3-(5-(2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl)thiazol-2-yl)urea methanesulfonate;N-(3-Chlorophenyl)-N'-[5-[2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl]-2-thiazolyl]urea methanesulfonate
|
C19H19ClN6O4S3 |
527.03996 | |
TCS PIM-1 4a
|
438190-29-5 |
(5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE
|
SMI-4A>97%;(5Z)-5-[[3-(三氟甲基)苯基]亚甲基]-2,4-噻唑烷二酮;SMI-4A;SMI4A;CS-1477;CS-2669;SMI-4A;SMI4A;(Z)-SMI4A;(Z)-SMI 4A
|
C11H6F3NO2S |
273 | 200-256-5 |
Sitagliptin Phosphate monohydrate
|
654671-77-9 |
磷酸西他列汀
|
磷酸西格列汀无水物;磷酸西格列汀一水物;磷酸西他列汀;磷酸西格列汀;磷酸西他司汀;磷酸西他列汀一水;MK-0432 PHOSPHATE MONOHYDRATE;磷酸西他列汀,西他列汀中间体;磷酸西他列汀,西格列汀中间体
|
C16H15F6N5O·H3PO4·H2O |
523.33 | 682-492-2 |
Sirtinol
|
410536-97-9 |
2-[[(2-羟基-1-萘基)亚甲基]氨基]-N-(1-苯基乙基)苯甲酰胺
|
SIRTINOL,去乙酰化酶;2-[[(2-羟基-1-萘基)亚甲基]氨基]-N-(1-苯基乙基)苯甲酰胺;去乙酰化酶;2-[(2-羟基萘-1-基亚甲基)氨基]-N-(1-苯乙基)苯甲酰胺
|
C26H22N2O2 |
394.47 | |
Sildenafil citrate
|
171599-83-0 |
枸橼酸西地那非
|
枸橼酸西地那非(伟哥、万艾可);枸橼酸西地那非 1KG;西地那非&远成;昔多芬杂质;1-[[3-(6,7-二氢-1-甲基-7-氧-3-丙基-1H-吡唑并-[4,3-d]嘧啶-5-基)-4-乙氧苯基]璜酰基]-5-甲基哌嗪柠檬酸盐;伟哥;西地那非枸橼酸;西地那非柠檬酸盐;万艾可
|
C22H30N6O4S.C6H8O7 |
666.69992 | 200-659-6 |
Safinamide Mesylate
|
202825-46-5 |
沙芬酰胺甲磺酸盐
|
沙芬酰胺甲磺酸盐;甲磺酸沙芬酰胺;甲磺酸沙芬酰胺(去甲磺酸133865-89-1);甲磺酸沙芬酰胺/沙芬酰胺甲磺酸盐;(S)-2-[4-(3-氟苄氧基)苄氨基]丙酰胺甲磺酸盐;沙酚酰胺甲磺酸盐
|
C18H23FN2O5S |
398.44902 | 606-485-0 |
Dolutegravir
|
1051375-16-6 |
度鲁特韦
|
BNKY001-DL04;杜洛韦杂质;(4R,12AS)-N-[(2,4-二氟苯基)甲基]-3,4,6,8,12,12A-六氢-7-羟基-4-甲基-6,8-二氧代-2H-吡啶并[1',2':4,5]吡嗪并[2,1-B][1,3]嗪-9-甲酰胺;多替拉韦;杜鲁特韦,德罗特韦;多特格伟;多替拉韦杂质1;度鲁特韦杂质
|
C20H19N3O5F2 |
419.37876 | 809-888-1 |
AG-014699 (Rucaparib)
|
459868-92-9 |
瑞卡帕布(AG-014699)
|
8-氟-2-{4-[(甲胺基)甲基]苯基}-1,3,4,5-四氢-6H-氮杂卓并[5,3-CD]吲哚-6-酮磷酸盐;AG-14699 (AS PHOSPHATE SALT); AG-014447 (AS FREE BASE); RUCAPARIB; PF-01367338; AG014699;瑞卡帕布磷酸盐;AG014699;RUCAPARIB PHOSPHATE;RUCAPARIB PHOSPHATE;AG014699 PHOSPHATE;PF01367338 PHOSPHATE;AG 014699 PHOSPHATE;PF 01367338 PHOSPHATE;AG-014699 PHOSPHATE;PF-01367338 PHOSPHATE;AG-014699;PF-01367338;8-氟-1,5-四氢-2-[4-[(甲基氨基)甲基]苯基]-6H-吡咯并[4,2-EF][2]苯并氮杂卓-6-酮磷酸盐
|
C19H18FN3O5P |
418.3354842 | -0 |
Rosiglitazone maleate
|
155141-29-0 |
马来酸罗格列酮
|
5-[4-[2-[N-甲基-N-(2-吡啶基)氨基]-乙氧基]苄基]噻唑烷-2,4二酮马来酸盐;马来酸罗格列酮;罗格列酮马来酸盐;马来酸罗格利酮;马来酸罗格列酮(标准品);马来酸罗格列酮(5-[4-[2-[N-甲基-N-(2-吡啶基)氨基]-乙氧基]苄基]噻唑烷-2,4二酮马来酸盐、罗格列酮马来酸盐、马来酸罗格利酮);马来酸罗格列酮溶液,100PPM;马来酸罗格列酮溶液,1001PPM
|
C22H23N3O7S |
473.12 | 642-163-6 |
romidepsin
|
128517-07-7 |
罗米地辛
|
罗米地辛;FK228 罗米地辛;罗米地辛,一种有效的HDAC1和HDAC2抑制剂;FK 228;FR 901228;NSC 630176;DEPSIPEPTIDE;FK229
|
C24H36N4O6S2 |
540.694 | |
rivaroxaban
|
366789-02-8 |
利伐沙班
|
5-氯-N-(((5S)-2-氧代-3-(4-(3-氧代吗啉-4-基)苯基)-1,3-恶唑啉-5-基)甲基)噻吩-2-甲酰胺;利伐沙班;5-氯-N-[[(5S)-2-氧代-3-[4-(3-氧代-4-吗啉基)苯基]-5-恶唑基]甲基]-2-噻吩甲酰胺;利伐沙班,5-氯-N-(((5S)-2-氧代-3-(4-(3-氧代吗啉-4-基)苯基)-1,3-恶唑啉-5-基)甲基)噻吩-2-甲酰胺;利伐沙班-D5;立伐沙班;RIVAROXABAN 利伐沙班
|
C19H18CLN3O5S |
435.88 | |
Resminostat
|
864814-88-0 |
RESMINOSTAT; 4SC-201; RAS2410
|
|
C16H19N3O4S |
349.411 | |
Sirolimus
|
53123-88-9 |
雷帕霉素
|
雷帕霉素;雷帕霉素-D3 (雷帕霉素-D3);雷帕霉素(98%细胞干扰;99%器官移植);雷帕霉素D3;雷帕霉素,来源于吸水链霉菌
|
C51H79NO13 |
914.18 |